Stock Analysis on Net
Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

Analysis of Liquidity Ratios
Quarterly Data

Beginner level

Liquidity Ratios (Summary)

Illumina Inc., liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Current ratio 3.88 3.76 4.10 6.69 6.82 6.79 3.66 2.49 2.46 2.74 2.71 3.99 4.22 3.88 3.49 3.29 3.62 3.69 4.31 3.43 3.79 3.09 2.90
Quick ratio 3.40 3.28 3.61 6.00 5.99 5.95 3.28 2.23 2.20 2.39 2.35 3.43 3.65 3.32 2.98 2.75 3.05 3.09 3.63 2.90 3.17 2.59 2.42
Cash ratio 2.98 2.93 3.16 5.13 5.11 5.18 2.91 1.95 1.95 2.06 2.01 2.88 3.07 2.78 2.47 2.21 2.44 2.45 2.79 2.27 2.47 2.08 1.92

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Illumina Inc.’s current ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Illumina Inc.’s quick ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Illumina Inc.’s cash ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020.

Current Ratio

Illumina Inc., current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Current assets 4,329  4,194  4,324  4,451  4,222  4,156  4,545  4,490  4,262  3,337  3,194  2,980  2,805  2,643  2,517  2,318  2,278  2,143  2,074  2,097  2,210  2,238  2,060 
Current liabilities 1,115  1,115  1,054  665  619  612  1,241  1,804  1,735  1,217  1,180  746  665  682  721  705  629  582  481  610  584  725  710 
Liquidity Ratio
Current ratio1 3.88 3.76 4.10 6.69 6.82 6.79 3.66 2.49 2.46 2.74 2.71 3.99 4.22 3.88 3.49 3.29 3.62 3.69 4.31 3.43 3.79 3.09 2.90
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.57 1.43 1.44 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17
AbbVie Inc. 0.86 3.14 3.18 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39
Amgen Inc. 2.28 2.18 1.59 1.44 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53
Biogen Inc. 2.06 2.46 1.73 1.72 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29 2.55 3.24 2.96 2.59 2.60 3.52 2.20 2.70
Bristol-Myers Squibb Co. 1.47 1.66 1.60 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94
Eli Lilly & Co. 1.36 1.22 1.11 1.16 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41
Gilead Sciences Inc. 2.33 3.04 3.10 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70
Johnson & Johnson 1.48 1.25 1.31 1.26 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44
Merck & Co. Inc. 1.32 1.11 1.24 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61
Pfizer Inc. 1.42 1.03 0.88 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45
Regeneron Pharmaceuticals Inc. 2.12 4.21 3.67 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31
Vertex Pharmaceuticals Inc. 3.72 3.72 3.54 3.61 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49
Zoetis Inc. 3.47 2.77 2.63 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 4,329 ÷ 1,115 = 3.88

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Illumina Inc.’s current ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020.

Quick Ratio

Illumina Inc., quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Cash and cash equivalents 1,761  1,770  1,991  2,042  1,815  1,943  2,270  1,144  1,346  1,344  1,560  1,225  1,354  1,219  981  735  795  952  755  769  552  591  534 
Short-term investments 1,563  1,498  1,341  1,372  1,351  1,230  1,345  2,368  2,043  1,168  813  920  687  674  797  824  742  474  588  617  888  919  833 
Accounts receivable, net 464  385  472  573  541  470  457  514  433  395  400  411  383  372  368  381  382  372  403  386  413  369  350 
Total quick assets 3,788  3,653  3,804  3,987  3,707  3,643  4,072  4,026  3,822  2,907  2,773  2,556  2,424  2,265  2,146  1,940  1,918  1,798  1,746  1,772  1,853  1,879  1,717 
 
Current liabilities 1,115  1,115  1,054  665  619  612  1,241  1,804  1,735  1,217  1,180  746  665  682  721  705  629  582  481  610  584  725  710 
Liquidity Ratio
Quick ratio1 3.40 3.28 3.61 6.00 5.99 5.95 3.28 2.23 2.20 2.39 2.35 3.43 3.65 3.32 2.98 2.75 3.05 3.09 3.63 2.90 3.17 2.59 2.42
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.93 0.83 0.88 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45
AbbVie Inc. 0.58 2.88 2.91 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10
Amgen Inc. 1.65 1.60 1.10 1.01 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68
Biogen Inc. 1.61 2.00 1.39 1.43 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57 1.94 2.44 2.16 1.91 1.93 2.84 1.57 1.98
Bristol-Myers Squibb Co. 1.26 1.38 1.26 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44
Eli Lilly & Co. 0.79 0.68 0.64 0.68 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95
Gilead Sciences Inc. 2.09 2.78 2.86 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17
Johnson & Johnson 1.17 0.92 0.98 0.94 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80
Merck & Co. Inc. 0.84 0.66 0.78 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09
Pfizer Inc. 0.98 0.60 0.50 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81
Regeneron Pharmaceuticals Inc. 1.61 3.38 2.81 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88
Vertex Pharmaceuticals Inc. 3.46 3.47 3.27 3.33 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17
Zoetis Inc. 2.39 1.69 1.67 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 3,788 ÷ 1,115 = 3.40

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Illumina Inc.’s quick ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020.

Cash Ratio

Illumina Inc., cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Cash and cash equivalents 1,761  1,770  1,991  2,042  1,815  1,943  2,270  1,144  1,346  1,344  1,560  1,225  1,354  1,219  981  735  795  952  755  769  552  591  534 
Short-term investments 1,563  1,498  1,341  1,372  1,351  1,230  1,345  2,368  2,043  1,168  813  920  687  674  797  824  742  474  588  617  888  919  833 
Total cash assets 3,324  3,268  3,332  3,414  3,166  3,173  3,615  3,512  3,389  2,512  2,373  2,145  2,041  1,893  1,778  1,559  1,536  1,425  1,343  1,386  1,439  1,510  1,366 
 
Current liabilities 1,115  1,115  1,054  665  619  612  1,241  1,804  1,735  1,217  1,180  746  665  682  721  705  629  582  481  610  584  725  710 
Liquidity Ratio
Cash ratio1 2.98 2.93 3.16 5.13 5.11 5.18 2.91 1.95 1.95 2.06 2.01 2.88 3.07 2.78 2.47 2.21 2.44 2.45 2.79 2.27 2.47 2.08 1.92
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.46 0.34 0.38 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07
AbbVie Inc. 0.25 2.50 2.56 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72
Amgen Inc. 1.24 1.09 0.68 0.69 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28
Biogen Inc. 0.94 1.26 0.83 0.92 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96 1.43 1.73 1.51 1.29 1.33 2.22 0.93 1.11
Bristol-Myers Squibb Co. 0.92 0.95 0.84 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99
Eli Lilly & Co. 0.30 0.20 0.14 0.21 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50
Gilead Sciences Inc. 1.79 2.34 2.50 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52
Johnson & Johnson 0.79 0.52 0.54 0.54 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31
Merck & Co. Inc. 0.50 0.32 0.47 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76
Pfizer Inc. 0.70 0.31 0.26 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37
Regeneron Pharmaceuticals Inc. 0.85 1.95 1.53 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38
Vertex Pharmaceuticals Inc. 3.07 3.03 2.72 2.85 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91
Zoetis Inc. 1.85 1.13 1.07 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,324 ÷ 1,115 = 2.98

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Illumina Inc.’s cash ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020.